Abstract
In reaction to the marketing suspension recommended by the European Medicines Agency, Genentech announced the voluntary withdrawal of efalizumab. Since June 8, 2009, efalizumab has been unavailable. Despite the fact that the use of efalizumab is now ceased, results of studies with efalizumab will remain relevant, especially about its use in an off-label setting for indications other then chronic plaque psoriasis. New biologics as well as chemicals are being developed targeting similar T-cell-mediated pathways. Indications for these new compounds other than chronic plaque psoriasis could be selected based on this systematic review. With this article we aimed to summarize the evidence of effectiveness and/or the efficacy and safety of efalizumab in off-label dermatological use, and to illustrate the time scale in which dermatological medicines are offered off-label to dermatological patients. We found some evidence supporting the effectiveness of efalizumab in palmoplantar pustulosis, atopic dermatitis, lic...
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
